Suchergebnisse

In 2016, the American Academy of Microbiology convened a colloquium to examine point-of-care (POC) microbiology testing and to evaluate its effects on clinical microbiology. Colloquium participants included representatives from clinical microbiology laboratories, industry, and the government, who together made recommendations regarding the implementation, oversight, and evaluation of POC microbiology testing. The colloquium report is timely and well written (V. Dolen et al., Changing Diagnostic Paradigms for Microbiology, 2017, https://www.asm.org/index.php/colloquium-reports/item/6421-changing-diagnostic-paradigms-for-microbiology?utm_source=Commentary&utm_medium=referral&utm_campaign=diagnostics). Emerging POC microbiology tests, especially nucleic acid amplification tests, have the potential to advance medical care.

In the late 1960s, Emil Gotschlich, a member of the laboratory of Maclyn McCarty, built on decades of Rockefeller research to develop effective vaccines against meningitis. From 1966 to 1968, Gotschlich developed novel methods to isolate highly purified meningococcal capsular polysaccharides from serotypes A, B, and C and showed that injection of 50 mg of group A or group C polysaccharide induced human beings to rapidly produce specific antibodies, and that these were able to kill meningococci. In 1970 he demonstrated the group C polysaccharide was 90 percent effective in preventing meningitis in military recruits. Photo by Lubosh Stepanek ; https://digitalcommons.rockefeller.edu/milestones_microbiology/1012/thumbnail.jpg

Advanced microbiology technologies are rapidly changing our ability to diagnose infections, improve patient care, and enhance clinical workflow. These tools are increasing the breadth, depth, and speed of diagnostic data generated per patient, and testing is being moved closer to the patient through rapid diagnostic technologies, including point-of-care (POC) technologies. While select stakeholders have an appreciation of the value/importance of improvements in the microbial diagnostic field, there remains a disconnect between clinicians and some payers and hospital administrators in terms of understanding the potential clinical utility of these novel technologies. Therefore, a key challenge for the clinical microbiology community is to clearly articulate the value proposition of these technologies to encourage payers to cover and hospitals to adopt advanced microbiology tests. Specific guidance on how to define and demonstrate clinical utility would be valuable. Addressing this challenge will require alignment on this topic, not just by microbiologists but also by primary care and emergency room (ER) physicians, infectious disease specialists, pharmacists, hospital administrators, and government entities with an interest in public health. In this article, we discuss how to best conduct clinical studies to demonstrate and communicate clinical utility to payers and to set reasonable expectations for what diagnostic manufacturers should be required to demonstrate to support reimbursement from commercial payers and utilization by hospital systems.

Microbes and their activities have pervasive, remarkably profound and generally positive effects on the functioning, and thus health and well-being, of human beings, the whole of the biological world, and indeed the entire surface of the planet and its atmosphere. Collectively, and to a significant extent in partnership with the sun, microbes are the life support system of the biosphere. This necessitates their due consideration in decisions that are taken by individuals and families in everyday life, as well as by individuals and responsible bodies at all levels and stages of community, national and planetary health assessment, planning, and the formulation of pertinent policies. However, unlike other subjects having a pervasive impact upon humankind, such as financial affairs, health, and transportation, of which there is a widespread understanding, knowledge of relevant microbial activities, how they impact our lives, and how they may be harnessed for the benefit of humankind - microbiology literacy - is lacking in the general population, and in the subsets thereof that constitute the decision makers. Choices involving microbial activity implications are often opaque, and the information available is sometimes biased and usually incomplete, and hence creates considerable uncertainty. As a consequence, even evidence-based 'best' decisions, not infrequently lead to unpredicted, unintended, and sometimes undesired outcomes. We therefore contend that microbiology literacy in society is indispensable for informed personal decisions, as well as for policy development in government and business, and for knowledgeable input of societal stakeholders in such policymaking. An understanding of key microbial activities is as essential for transitioning from childhood to adulthood as some subjects currently taught at school, and must therefore be acquired during general education. Microbiology literacy needs to become part of the world citizen job description. To facilitate the attainment of microbiology literacy in ...

Advanced microbiology technologies are rapidly changing our ability to diagnose infections, improve patient care, and enhance clinical workflow. These tools are increasing the breadth, depth, and speed of diagnostic data generated per patient, and testing is being moved closer to the patient through rapid diagnostic technologies, including point-of-care (POC) technologies. While select stakeholders have an appreciation of the value/importance of improvements in the microbial diagnostic field, there remains a disconnect between clinicians and some payers and hospital administrators in terms of understanding the potential clinical utility of these novel technologies. Therefore, a key challenge for the clinical microbiology community is to clearly articulate the value proposition of these technologies to encourage payers to cover and hospitals to adopt advanced microbiology tests. Specific guidance on how to define and demonstrate clinical utility would be valuable. Addressing this challenge will require alignment on this topic, not just by microbiologists but also by primary care and emergency room (ER) physicians, infectious disease specialists, pharmacists, hospital administrators, and government entities with an interest in public health. In this article, we discuss how to best conduct clinical studies to demonstrate and communicate clinical utility to payers and to set reasonable expectations for what diagnostic manufacturers should be required to demonstrate to support reimbursement from commercial payers and utilization by hospital systems.

Microbes and their activities have pervasive, remarkably profound and generally positive effects on the functioning, and thus health and well‐being, of human beings, the whole of the biological world, and indeed the entire surface of the planet and its atmosphere. Collectively, and to a significant extent in partnership with the sun, microbes are the life support system of the biosphere. This necessitates their due consideration in decisions that are taken by individuals and families in everyday life, as well as by individuals and responsible bodies at all levels and stages of community, national and planetary health assessment, planning, and the formulation of pertinent policies. However, unlike other subjects having a pervasive impact upon humankind, such as financial affairs, health, and transportation, of which there is a widespread understanding, knowledge of relevant microbial activities, how they impact our lives, and how they may be harnessed for the benefit of humankind – microbiology literacy – is lacking in the general population, and in the subsets thereof that constitute the decision makers. Choices involving microbial activity implications are often opaque, and the information available is sometimes biased and usually incomplete, and hence creates considerable uncertainty. As a consequence, even evidence‐based 'best' decisions, not infrequently lead to unpredicted, unintended, and sometimes undesired outcomes. We therefore contend that microbiology literacy in society is indispensable for informed personal decisions, as well as for policy development in government and business, and for knowledgeable input of societal stakeholders in such policymaking. An understanding of key microbial activities is as essential for transitioning from childhood to adulthood as some subjects currently taught at school, and must therefore be acquired during general education. Microbiology literacy needs to become part of the world citizen job description. To facilitate the attainment of microbiology literacy in ...

16 p.-1 fig. ; Microbes and their activities have pervasive, remarkably profound and generally positive effects on the functioning, and thus health and well‐being, of human beings, the whole of the biological world, and indeed the entire surface of the planet and its atmosphere. Collectively, and to a significant extent in partnership with the sun, microbes are the life support system of the biosphere. This necessitates their due consideration in decisions that are taken by individuals and families in everyday life, as well as by individuals and responsible bodies at all levels and stages of community, national and planetary health assessment, planning, and the formulation of pertinent policies. However, unlike other subjects having a pervasive impact upon humankind, such as financial affairs, health, and transportation, of which there is a widespread understanding, knowledge of relevant microbial activities, how they impact our lives, and how they may be harnessed for the benefit of humankind – microbiology literacy – is lacking in the general population, and in the subsets thereof that constitute the decision makers. Choices involving microbial activity implications are often opaque, and the information available is sometimes biased and usually incomplete, and hence creates considerable uncertainty. As a consequence, even evidence‐based 'best' decisions, not infrequently lead to unpredicted, unintended, and sometimes undesired outcomes. We therefore contend that microbiology literacy in society is indispensable for informed personal decisions, as well as for policy development in government and business, and for knowledgeable input of societal stakeholders in such policymaking. An understanding of key microbial activities is as essential for transitioning from childhood to adulthood as some subjects currently taught at school, and must therefore be acquired during general education. Microbiology literacy needs to become part of the world citizen job description. To facilitate the attainment of microbiology literacy in society, through its incorporation into education curricula, we propose here a basic teaching concept and format that are adaptable to all ages, from pre‐school to high school, and places key microbial activities in the contexts of how they affect our everyday lives, of relevant Grand Challenges facing humanity and planet Earth, and of sustainability and Sustainable Development Goals. We exhort microbiologists, microbiological learned societies and microbiology‐literate professionals, to participate in and contribute to this initiative by helping to evolve the basic concept, developing and seeking funding to develop child‐friendly, appealing teaching tools and materials, enhancing its impact and, most importantly, convincing educators, policy makers, business leaders and relevant governmental and non‐governmental agencies to support and promote this initiative. Microbiology literacy in society must become reality. ; Peer reviewed

Quality management in clinical microbiology began in the 1960s. Both government and professional societies introduced programs for proficiency testing and laboratory inspection and accreditation. Many laboratory scientists and pathologists were independently active and creative in expanding efforts to monitor and improve practices. The initial emphasis was placed on intralaboratory process. Later, attention was shifted to physician ordering, specimen collection, reporting, and use of information. Quality management in the laboratory depends in large part on the monitoring of indicators that provide some evidence of how laboratory resources are being used and how the information benefits patient care. Continuous quality improvement should be introduced. This consists of a more thorough assessment of doing the right things versus the wrong things in terms of customer demand and satisfaction and studying the cumulative effect of error when responsibility is passed from one person to another. Prevention of error is accomplished more through effective training and continuing education than through surveillance. Also, this system will force more conscious attention to meeting the expectations of the many customers that must be satisfied by laboratory services, including patients, physicians, third-party payers, and managed-care organizations.

A retrospective analysis of the experiences of two military hospitals over 4 years in the recovery of organisms from biliary tract specimens was done. Bacterial growth was obtained in 123 bile specimens. Aerobic and facultative bacteria only were present in 59 specimens (48%), aerobic bacteria only were present in 4 specimens (3%), and mixed anaerobic and aerobic or facultative bacteria were present in 60 specimens (49%). Of 286 isolates recovered, 216 were aerobic or facultative (1.8 per specimen) and 70 were anaerobic (0.6 per specimen). The predominant bacteria were Escherichia coli (71 isolates), group D streptococci (42 isolates), Klebsiella sp. (29 isolates), Clostridium sp. (27 isolates), Bacteroides sp. (28 isolates), and Enterobacter sp. (16 isolates). Polymicrobial infections were present in 108 instances (88%). A higher recovery rate of anaerobes was present in patients with chronic infections than in those with acute infections and did not correlate with the presence of gallstones or use of antimicrobial prophylaxis.

In whey cheese manufacture, whey, plain or added with milk, is heated by direct fire, bubbling steam or alternatively in jacketed vats. In some cases, salt s or organic acids are previously added. At 80-85 OC, the first particles of curd form; at 85-95 'C, the curd may be cooked for a few minutes to reduce moisture content and/or to obtain the desirable level of browning. After drainage at room temperature during molding for ca. 4 h, whey cheese is stored at ca. 4 'C. The typical mass yield is 6%, but addition of milk, calcium salts and preliminary concentration of protein (by condensation or ultrafiltration techniques) may increase yield considerably. Some types of whey cheeses are supposed to be consumed within a short time upon manufacture (e.g., Ricotta, Requeijdo and Manouri), whereas others bear a longer shelf life (e.g., Gjetost, Mysost and Myzithra). Whey cheeses are significantly different from one another in terms of chemical composition, which is mainly due to variations in the source and type of whey, as well as to the processing practices followed. Moisture content and pH of whey cheeses are usually high and favor microorganism growth (molds, yeasts, lactic acid bacteria and Enterobacteriaceae account for the dominant microflora in these cheeses). Adequate packaging of whey cheeses should be provided, and legislation should be prepared to fix standard characteristics of each type of whey cheese, and hence protect typical products from adulteration and fakes. Marketing efforts should also be aimed at increasing whey cheese consumption, either directly or incorporated in desserts, snack dips and pasta-type dishes.

Dissertation presented to obtain the Ph.D degree in Engineering and Technology Sciences, Biotechnology. ; Water is a natural resource essential for life maintenance of the human kind and the ecosystems found in Nature. Currently the natural resources of water are increasingly exhausted with the constant water demand. Biological wastewater treatment processes are green, economic and efficient ways to remove pollutants from wastewater and recycle the water back into the environment. Membrane bioreactors (MBRs) in the last two decades have gained special attention due to the small footprint and the high quality of the treated effluent, helping meeting the requirements of increasingly stricter legislations. MBRs combine the activated sludge process with membrane filtration and have specific features that likely affect the microbial structure and ecophysiology.(.)

Modernization has thrown humanity and other forms of life on our planet into a ditch of problems. Poverty, climate change, injustice and environmental degradation are a few of the shared global problems. The United Nations Sustainable Development Goals (SDGs) are the blueprint to achieve a better and more sustainable future for all. The SDGs are well structured to address the global challenges we face including poverty, inequalities, hunger, climate change, environmental degradation, peace and justice. Five years into the implementation, the SDGs have been driven mainly by international donors and 'professional' international development organizations. The world is left with 10 years to achieve these ambitious goals and targets. Various reviews show that little has been achieved overall, and the SDGs will not be a reality if a new strategy is not in place to bring inclusion. Microbiology, the scientific discipline of microbes, their effects and practical uses has insightful influence on our day-to-day living. We present how microbiology and microbiologists could increase the scorecard and accelerate these global goals. Microbiology has a direct link to achieving SDGs addressing food security, health and wellbeing, clean energy, environmental degradation and climate change. A non-classical growing relationship exists between microbiology and other SDGs such as peace, justice, gender equality, decent work and economic growth. The pledge of 'Leave No One Behind' will fast track progress and microbiology is in a better position to make this work.

Background: There is wide variation in the availability and training of specialists in the diagnosis and management of infections across Europe. Objectives: To describe and reflect on the current objectives, structure and content of European curricula and examinations for the training and assessment of medical specialists in Clinical (Medical) Microbiology (CM/MM) and Infectious Diseases (ID). Sources: Narrative review of developments over the past two decades and related policy documents and scientific literature. Content: Responsibility for curricula and examinations lies with the European Union of Medical Specialists (UEMS). The ID Section of UEMS was inaugurated in 1997 and the MM Section separated from Laboratory Medicine in 2008. The sections collaborate closely with each other and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Updated European Training Requirements (ETR) were approved for MM in 2017 and ID in 2018. These comprehensive curricula outline the framework for delivery of specialist training and quality control for trainers and training programmes, emphasizing the need for documented, regular formative reviews of progress of trainees. Competencies to be achieved include both specialty-related and generic knowledge, skills and professional behaviours. The indicative length of training is typically 5 years; a year of clinical training is mandated for CM/MM trainees and 6 months of microbiology laboratory training for ID trainees. Each Section is developing examinations using multiple choice questions to test the knowledge base defined in their ETR, to be delivered in 2022 following pilot examinations in 2021. Implications: The revised ETRs and European examinations for medical specialists in CM/MM and ID provide benchmarks for national authorities to adapt or adopt locally. Through harmonization of postgraduate training and assessment, they support the promotion and recognition of high standards of clinical practice and hence improved care for patients throughout Europe, and improved mobility of trainees and specialists. Nick J. Beeching, Clin Microbiol Infect 2021;27:1581 (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

International audience ; Microorganisms spread across national boundaries and the professional activities of clinical (medical) microbiologists are critical in minimising their impact. Clinical microbiologists participate in many activities, e.g. diagnosis, antibiotic therapy, and there is a need for a set of professional standards for Europe with a common curriculum, to build upon the current strengths of the specialty and to facilitate the free movement of specialists within the European Union. Such standards will also better highlight the important contribution of clinical microbiologists to healthcare. There is a move to larger centralised microbiology laboratories often located off-site from an acute hospital, driven by the concentration of resources, amalgamation of services, outsourcing of diagnostics, automation, an explosion in the range of staff competencies and accreditation. Large off-site centralised microbiology laboratories are often distant to the patient and may not facilitate the early detection of microbial spread. Ultimately, the needs of patients and the public are paramount in deciding on the future direction of clinical microbiology. Potential conflicts between integration on an acute hospital site and centralisation can be resolved by a common set of professional standards and a team-based approach that puts patients first.

In an era of global health threats caused by epidemics of infectious diseases and rising multidrug resistance, microbiology laboratories provide essential scientific evidence for risk assessment, prevention, and control. Microbiology has been at the core of European infectious disease surveillance networks for decades. Since 2010, these networks have been coordinated by the European Centre for Disease Prevention and Control (ECDC). Activities delivered in these networks include harmonization of laboratory diagnostic, antimicrobial susceptibility and molecular typing methods, multicentre method validation, technical capacity mapping, training of laboratory staff, and continuing quality assessment of laboratory testing. Cooperation among the European laboratory networks in the past 7 years has proved successful in strengthening epidemic preparedness by enabling adaptive capabilities for rapid detection of emerging pathogens across Europe. In partnership with food safety authorities, international public health agencies and learned societies, ECDC-supported laboratory networks have also progressed harmonization of routinely used antimicrobial susceptibility and molecular typing methods, thereby significantly advancing the quality, comparability and precision of microbiological information gathered by ECDC for surveillance for zoonotic diseases and multidrug-resistant pathogens in Europe. ECDC continues to act as a catalyst for sustaining continuous practice improvements and strengthening wider access to laboratory capacity across the European Union. Key priorities include optimization and broader use of rapid diagnostics, further integration of whole-genome sequencing in surveillance and electronic linkage of laboratory and public health systems. This article highlights some of the network contributions to public health in Europe and the role that ECDC plays managing these networks.